Insider Transactions in Q1 2023 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,420
-1.02%
|
$53,960
$38.62 P/Share
|
|
Mar 28
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.46%
|
$19,912
$38.62 P/Share
|
|
Mar 23
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,224
-2.95%
|
$156,288
$37.82 P/Share
|
|
Mar 23
2023
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,455
-6.51%
|
$645,835
$37.82 P/Share
|
|
Mar 23
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,452
-2.13%
|
$90,724
$37.82 P/Share
|
|
Mar 07
2023
|
Nikhil Lalwani PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,662
-2.45%
|
$601,128
$44.23 P/Share
|
|
Mar 07
2023
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,503
-1.2%
|
$154,132
$44.23 P/Share
|
|
Mar 07
2023
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,342
-3.26%
|
$103,048
$44.23 P/Share
|
|
Mar 07
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,902
-2.43%
|
$83,688
$44.23 P/Share
|
|
Mar 07
2023
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
2,460
-1.05%
|
$108,240
$44.23 P/Share
|
|
Feb 28
2023
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,526
+10.71%
|
-
|
|
Feb 28
2023
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
159,216
+17.53%
|
-
|
|
Feb 28
2023
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
21,710
+7.76%
|
-
|
|
Feb 28
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+19.4%
|
-
|
|
Feb 28
2023
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+26.14%
|
-
|
|
Feb 28
2023
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
BUY
Grant, award, or other acquisition
|
Direct |
20,262
+22.45%
|
-
|
|
Feb 28
2023
|
Krista Davis SVP, CHIEF HR OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,262
+23.96%
|
-
|
|
Feb 28
2023
|
Chad Gassert SVP - CORP. DEV. & STRATEGY |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+39.29%
|
-
|
|
Feb 28
2023
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
28,947
+20.39%
|
-
|
|
Feb 15
2023
|
Ori Gutwerg SVP, GENERICS |
SELL
Payment of exercise price or tax liability
|
Direct |
1,275
-3.39%
|
$57,375
$45.04 P/Share
|
|
Feb 15
2023
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Payment of exercise price or tax liability
|
Direct |
1,292
-3.16%
|
$58,140
$45.04 P/Share
|